This board's been pretty dead. Roche signed a deal for ITMN's HCV PI before it was even in humans. Stock price is back in the low 20s on the deal. Now the PI starts:
>>InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche
Tuesday December 19, 12:40 pm ET
BRISBANE, Calif., Dec. 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) announced today that the company and its partner Roche have received approval of the European Clinical Trial Authorization (CTA) for ITMN-191, the NS3/4A protease inhibitor, and have initiated a Phase 1a clinical trial evaluating ITMN-191 for the treatment of chronic hepatitis C virus (HCV) infection. The Phase 1a trial will assess safety, tolerability, pharmacokinetics and food affect in a double-blind, placebo-controlled single ascending dose study. The study is being conducted at one clinical trial site in Europe and will enroll approximately 74 healthy volunteers. InterMune expects to dose the first patient with ITMN-191 sometime in early January 2007.
"Our preclinical research indicates ITMN-191 has the potential to be an important addition to therapy for HCV patients because of its favorable cross resistance and potency profiles, as well as pharmacokinetic results that support the exploration of twice-daily oral dosing in future clinical trials," said Lawrence M. Blatt, Ph.D., Chief Scientific Officer of InterMune. "The initiation of the Phase 1a human trial for ITMN-191 moves our HCV protease inhibitor program one step closer to the proof-of-concept Phase 1b clinical study in patients infected with HCV. We look forward to providing updates as we advance the program with our partner Roche."<<
snip
This one is still in the more or less defunct Biotech Lock-Up Expiration Hell Portfolio, which had a cost basis of (gulp) $28, I think. There's talk of bringing the portfolio feature back to SI, so who knows? Maybe BLUE HP will ride again.
Cheers, Tuck |
